294 related articles for article (PubMed ID: 35742910)
21. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
22. An individualized approach to the management of Cushing disease.
Fleseriu M; Varlamov EV; Hinojosa-Amaya JM; Langlois F; Melmed S
Nat Rev Endocrinol; 2023 Oct; 19(10):581-599. PubMed ID: 37537306
[TBL] [Abstract][Full Text] [Related]
23. Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism.
Khawandanah D; ElAsmar N; Arafah BM
Endocrine; 2019 Jan; 63(1):140-148. PubMed ID: 30259310
[TBL] [Abstract][Full Text] [Related]
24. [Corticotroph adenoma].
Guignat L; Assie G; Bertagna X; Bertherat J
Presse Med; 2009 Jan; 38(1):125-32. PubMed ID: 19041214
[TBL] [Abstract][Full Text] [Related]
25. Glucocorticoid inhibition of ACTH peptides: small cell lung cancer cell lines are more resistant than pituitary corticotroph adenoma cells.
Farrell WE; Stewart MF; Clark AJ; Crosby SR; Davis JR; White A
J Mol Endocrinol; 1993 Feb; 10(1):25-32. PubMed ID: 8383976
[TBL] [Abstract][Full Text] [Related]
26. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay.
Kojima Y; Suzuki S; Yamamura K; Ohhashi G; Yamamoto I
Endocr J; 2002 Jun; 49(3):285-92. PubMed ID: 12201210
[TBL] [Abstract][Full Text] [Related]
27. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
29. Cushing's disease and pregnancy.
Polli N; Pecori Giraldi F; Cavagnini F
Pituitary; 2004; 7(4):237-41. PubMed ID: 16132201
[No Abstract] [Full Text] [Related]
30. Paediatric Cushing's disease: long-term outcome and predictors of recurrence.
Savage MO; Ferrigno R
Front Endocrinol (Lausanne); 2024; 15():1345174. PubMed ID: 38318299
[TBL] [Abstract][Full Text] [Related]
31. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
32. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
33. [The ectopic ACTH syndrome].
Penezić Z; Savić S; Vujović S; Tatić S; Ercegovac M; Drezgićc M
Srp Arh Celok Lek; 2004; 132(1-2):28-32. PubMed ID: 15227962
[TBL] [Abstract][Full Text] [Related]
34. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
[TBL] [Abstract][Full Text] [Related]
35. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus.
Huizenga NA; de Lange P; Koper JW; Clayton RN; Farrell WE; van der Lely AJ; Brinkmann AO; de Jong FH; Lamberts SW
J Clin Endocrinol Metab; 1998 Mar; 83(3):917-21. PubMed ID: 9506748
[TBL] [Abstract][Full Text] [Related]
36. Pituitary-adrenal dynamics after ACTH-secreting pituitary tumor resection in patients receiving no steroids post-operatively.
Pimentel-Filho FR; Silva ME; Nogueira KC; Berger K; Cukiert A; Liberman B
J Endocrinol Invest; 2005 Jun; 28(6):502-8. PubMed ID: 16117190
[TBL] [Abstract][Full Text] [Related]
37. The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.
Fukuoka H; Shichi H; Yamamoto M; Takahashi Y
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266265
[TBL] [Abstract][Full Text] [Related]
38. High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma.
Comtois R; Beauregard H; Hardy J; Robert F; Somma M
Clin Endocrinol (Oxf); 1993 Jun; 38(6):601-7. PubMed ID: 8392915
[TBL] [Abstract][Full Text] [Related]
39. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
40. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.
Fleseriu M; Findling JW; Koch CA; Schlaffer SM; Buchfelder M; Gross C
J Clin Endocrinol Metab; 2014 Oct; 99(10):3718-27. PubMed ID: 25013998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
